Health tech company Flatiron Health, an independent affiliate of the Roche Group, is expanding the reach of its clinical data ...

Cell therapy biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

The brain-computer interface developer Synchron has laid out plans to build an artificial intelligence model trained on the language of cognition—instead of words or pictures—with programs that are ...

Empress Therapeutics is halving its team, letting go of 23 employees as the biotech works to get its small-molecule science ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...